Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,645 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
The Board Meeting to be held on 22/05/2026 has been revised to 26/05/2026 The Board Meeting to be held on 22/05/2026 has been revised to 26/05/2026
Regulatory Filings Classification · 85% confidence The document is a formal intimation to stock exchanges under SEBI Listing Regulations about the rescheduling of a Board of Directors meeting to approve audited financial results and recommend dividends. It contains no financial data, no management changes, and no report itself—just a regulatory notice. This fits the general “Regulatory Filings” category for miscellaneous compliance disclosures under LODR Regulation 29.
2026-05-21 English
General Updates
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI Listing Regulations (Regulation 30) notifying stock exchanges of a board-approved share transfer in a subsidiary, i.e. a regulatory announcement rather than an actual financial report or a management presentation. It does not present financial statements or call transcripts, nor is it an AGM, earnings release, or dividend notice. None of the more specific categories (e.g., share issue/capital change, insider dealing, M&A) perfectly match this routine compliance disclosure. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-20 English
Please find attached the file
Major Shareholding Notification Classification · 75% confidence The document is an intimation under SEBI Listing Regulations concerning the transfer of subsidiary shares and a consequent change in the company’s percentage ownership (from 60% to 51%) as well as changes in shareholding pattern of the subsidiary. This is a notification of changes in significant share ownership levels (crossing thresholds) rather than a share issuance, buyback, dividend notice, earnings release, or other category. It best fits the “Major Shareholding Notification” category (Code: MRQ).
2026-05-20 English
Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve Q-4 and FY 2026 Results.
Regulatory Filings Classification · 88% confidence The document is a notice under SEBI Listing Obligations (Regulation 29) informing exchanges of a scheduled Board meeting to consider and approve audited financial results. It contains no actual financial data nor any change in board composition. This is a standard regulatory filing/intimation rather than the financial report itself or any other event-specific category. Thus it falls under the generic Regulatory Filings category (RNS).
2026-05-15 English
Please find enclosed Annual Secretarial Compliance Report for the financial year ended on March 31, 2026.
Regulatory Filings Classification · 90% confidence The document is titled “Annual Secretarial Compliance Report for the financial year ended 31st March 2026” prepared by a Practicing Company Secretary under SEBI Listing Regulations. It is an attestation/certification of regulatory compliance rather than a financial statement or management discussion. It does not present substantive financial data but confirms adherence to various listing obligations and is submitted as a statutory/regulatory filing. Under the classification rules, this falls into the general regulatory filings category (RNS).
2026-05-11 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended 31st March 2026' and is issued pursuant to SEBI regulations related to the monitoring of proceeds from a Qualified Institutions Placement (QIP). It is prepared by CARE Ratings Limited, the appointed Monitoring Agency, and details the utilization of funds raised through the QIP. The report includes detailed tables on the use of proceeds, deviations, and compliance with the offer document. The document is about monitoring the use of capital raised and is not a full financial report like an Annual or Interim Report. It is not an announcement or a brief notice but a substantive report on the monitoring of capital utilization. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including monitoring agency reports related to capital raising.
2026-05-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.